Omeros (OMER) Other financing activities (2010 - 2025)

Omeros (OMER) posted Other financing activities of $115.5 million for Q1 2024, up 5204.18% sequentially from $2.2 million in Q3 2020.

Analysis

Omeros (OMER) Other financing activities (2010 - 2025) Analysis & Trends

Omeros has reported Other financing activities for 10 years, with the latest figure at $115.5 million in Q1 2024.

Quarterly Other financing activities changed N/A year-over-year to $115.5 million in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $115.5 million (changed N/A YoY) and the FY2024 annual result came in at $115.5 million, changed N/A from the prior year.
Other financing activities grew to $115.5 million in Q1 2024 per OMER's latest filing, from $2.2 million in the prior quarter.
Over five years, Other financing activities peaked at $115.5 million in Q1 2024 and troughed at $88000.0 in Q2 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Omeros	1.38 Bn	1.38 Bn	27.73 Mn

Historic Data

Download Data